Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-07-03
2007-07-03
Ungar, Susan (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
Reexamination Certificate
active
10662044
ABSTRACT:
The invention relates to antibodies that bind to antigens, such as antigens associated with hyperproliferating cells, and methods of treating hyperproliferative disorders. The invention antibodies are useful for treating hyperproliferative disorders, such as neoplasia.
REFERENCES:
White et al. (2001, Ann. Rev. Med. 52:125-145).
2005, Temporary protocol of treatment: Trastuzumab (Herceptin®) in adjuvant conditions, Institut National du Cancer and Agence francaise de securite sanitaire des produits de sante, www.e-cancer.fr/medias/pttdefeng2710.pdf.
Busken et al. (2003, Digestive Disease Week Abstracts and Itinerary Planner, abstract No. 850).
Cotterchio et al, 2000, Chronic Diseases in Canada, (Electronic Version downloaded from http://www.phac-aspc.gc.ca/publicat/cdic-mcc/21-2/f—e.html).
Apantaku, Breast cancer diagnosis and screening, American Family Physician (2000). (Electronic version, downloaded from http://www.healthlibrary.com/doctors2/breastcancer2.html).
Martin et al (Journal of the National Cancer Institute, 92:1126-1135).
Gura, 1997, Science 278:1041-1042.
Apantaku, L.M., “Breast cancer diagnosis and screening,” American Family Physician Aug. 1, 2000,; 62(3):596-602, 605-6. (Electronic version downloaded from http://www.healthlibrary.com/doctors2/breastcancer2.html.
Buskens, C. et al., “Adenocarcinomas of the Gastro-Esophageal Junction: A Comparative Study of the Gastric Cardia and the Esophagus with Respect to Cyclooxygenase-2 Expression,” Digestive Disease Week Abstracts and Itinerary Planner, vol. 2003, abstract No. 850, 2003, e-file.
Cotterchio, M. et al., “Ontario Familial Colon Cancer Registry: Methods and First-year Response Rates,” Chronic Diseases in Canada vol. 21, No. 2, 2000 (electronic version downloaded from http://www.phac-aspc.gc.ca/publicat/cdic-mcc/21-2/f—e.html.
Gura, T., “Systems for Identifiyng New Drugs Are Often Faulty,” Science vol. 278:1041-1042, Nov. 7, 1997.
Martin, A. and Weber, B.L., “Genetic and Hormonal Risk Factors in Breast Cancer,” J. of the National Cancer Inst., vol. 92, No. 14, Jul. 19, 2000.
White, C.A., et al., “Antibody-Targeted Immunotherapy for Treatment of Malignancy,” Annu. Rev. Med. 2001, 52:125-45.
Oct. 2005, “Temporary protocol of treatment: Trastuzumab (Herceptin®) in adjuvant conditions,” Institu National de Cancer and Agence francaise de securite sanitaire des produits de sante, www.e-cancer.fr/medias/pttdefeng2710.pdf.
Chakrabarti Subhra
Glassy Mark C.
Mukerjee Sonjoy
Joyce Catherine
Shantha West, Inc.
Ungar Susan
Wilson Sonsini Goodrich & Rosati
LandOfFree
Antibodies that recognize hyperproliferative cells and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies that recognize hyperproliferative cells and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies that recognize hyperproliferative cells and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3750769